Vitality Watch

Dossier pubmed trial early 16-jul-2026
Small or early-phase human trial or pilot study

Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol.

Key claim: A phase 2a randomized trial will test whether oral β-NMN (MIB-626, 1000 mg twice daily for 24 weeks) improves urinary albumin-to-creatinine ratio and related kidney and biological-age markers in adults with diabetic kidney disease.

Abstract

INTRODUCTION: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and kidney failure worldwide. Reduced nicotinamide adenine dinucleotide (NAD) levels are mechanistically linked to DKD pathogenesis; and NAD augmentation by administration of its precursor, nicotinamide mononucleotide (NMN), has attenuated albuminuria and kidney injury in preclinical models. METHODS: The NAD Augmentation in Diabetic Kidney Disease (NAD in DKD) trial is a phase 2a, randomized, multicenter, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of oral pharmaceutical-grade microcrystalline β-NMN (MIB-626) in adults with DKD. One hundred fifty-six participants aged ≥ 30 years with diabetes, urinary albumin-to-creatinine ratio (UACR) ≥ 100 mg/g, and estimated glomerular filtration rate (eGFR) > 25 ml/min per 1.73 mwere randomized to receive MIB-626 (1000 mg twice daily) or placebo for 24 weeks, followed by 12 weeks of postintervention follow-up. The randomization was stratified for biological sex, age (30-44, 45-65, and ≥ 66 years), and enrolling site. The primary end point was change in UACR from baseline to 24 weeks. Secondary outcomes included serum creatinine, cystatin C, and eGFR, biomarkers of kidney injury and biological age, glycemic control, measures of muscle performance and physical function, and the circulating NAD metabolome. CONCLUSION: This phase 2a trial was designed to evaluate the safety and efficacy of NAD augmentation in improving UACR in albuminuric DKD. The results will inform whether NAD augmentation warrants further evaluation in larger trials statistically powered for long-term kidney outcomes. The study is registered at ClinicalTrials.gov (NCT05759468).

Why this matters

Most NAD+ precursor human data to date rests on surrogate endpoints like NAD+ levels or epigenetic clocks in healthy adults; this is one of the first phase 2a RCTs to put pharmaceutical-grade NMN (MIB-626) against a disease-defining clinical biomarker (albuminuria in diabetic kidney disease). The protocol itself signals that NAD precursors are moving from supplement-aisle framing into regulated drug-development pipelines, though no efficacy conclusion can be drawn until results report.

Source

Link

Briefing card

Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol.
Stage: trial early · pubmed · 16-jul-2026

If you take NMN for general longevity, this is a trial protocol — not results — testing whether a pharmaceutical NMN improves kidney markers in people with diabetic kidney disease.

A phase 2a randomized trial will test whether oral β-NMN (MIB-626, 1000 mg twice daily for 24 weeks) improves urinary albumin-to-creatinine ratio and related kidney and biological-age markers in adults with diabetic kidney disease.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.ekir.2026.106700

build build 880 · 2bcef25 · 2026-11-18